ALLR · NASDAQ · Biotechnology

Allarity Therapeutics (ALLR)

Develops stenoparib with DRP®-guided patient selection for advanced recurrent ovarian cancer.

$1.41
Pre-market−0.01 (−0.70%)
At close$1.42(0.00%)

Something off on this page? Send us feedback.

Next report
Nov 13, 2026
estimated · in 71 days
EPS estimate
−$0.25
Revenue estimate
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Apr '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$4.73−$0.25−$0.15−$0.19−$0.19−$0.17−$0.21Pending
Estimate−$8.10−$0.21−$0.23−$0.22−$0.22−$0.25−$0.25
Surprise+41.6%+28.6%+17.4%+13.6%+22.7%+16.0%

RevenueReportedEstimate

Apr '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$6.0K$320.0K$25.0KPending
Estimate$320.0K$25.0K
Surprise0.0%0.0%

History

DateEstimateReportedSurprise
Nov 2026−$0.25
Aug 2026−$0.25−$0.21+16.0%
May 2026−$0.22−$0.17+22.7%
Mar 2026−$0.22−$0.19+13.6%
Nov 2025−$0.23−$0.19+17.4%

The latest year is open to everyone — the 22 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Apr 2025
Nov 2024
Aug 2024
May 2024
Apr 2024
Nov 2023
Aug 2023
May 2023
Mar 2023
Nov 2022
Oct 2022
May 2022
May 2022
Nov 2021
Jun 2021
Mar 2021
Dec 2020
Sep 2020
Dec 2019
Sep 2015
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Nov 13, 2026−$0.25
Aug 14, 2026−$0.25−$0.21+16.0%+0.7%
May 15, 2026−$0.22−$0.17+22.7%$25.0K$25.0K0.0%+5.9%
Mar 31, 2026−$0.22−$0.19+13.6%$320.0K$320.0K0.0%+3.7%
Nov 14, 2025−$0.23−$0.19+17.4%−5.1%

The latest year is open to everyone — the 22 quarters behind it read with an account.

Sign in
Aug 15, 2025
May 9, 2025
Apr 4, 2025
Nov 14, 2024
Aug 5, 2024
May 14, 2024
Apr 29, 2024
Nov 14, 2023
Aug 14, 2023
May 11, 2023
Mar 13, 2023
Nov 14, 2022
Oct 7, 2022
May 27, 2022
May 17, 2022
Nov 23, 2021
Jun 30, 2021
Mar 31, 2021
Dec 31, 2020
Sep 30, 2020
Dec 31, 2019
Sep 30, 2015